Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review, 2019

Schizophrenia is a severe and chronic mental disorder that affects the individual’s ability to think clearly, make decisions, and manage emotions. Cognitive impairment is among the core symptoms of schizophrenia. Cognitive impairment associated with schizophrenia results in deficits in memory, attention, and executive function, which negatively impacts the quality of life of patients. According to WHO, schizophrenia affects more than 21 million people in the world, which emphasize the need for novel drugs for its treatment.

There are no pharmacological agents for the treatment of Schizophrenia. Current treatment is focused on reducing or eliminating the symptoms of the disease. Antipsychotics drugs in the form of pills or injection are usually prescribed for the management of the cognitive impairment associated with schizophrenia.

Large unmet needs of the patient population hold potential future business opportunity for pharmaceutical manufacturers. As the existing treatment modalities fail to treat the cognitive impairment symptoms, many pharmaceutical companies and research institutes are now focusing on developing new therapies. For instance; BIIB104, which is being studied by Biogen is currently in phase 2 clinical trials to evaluate its efficacy and safety in patients with cognitive impairment associated with schizophrenia.

At present, around 67% of the pipeline candidates for Cognitive Impairment Associated with Schizophrenia (CIAS) are in phase 2 clinical stage. More than half of the studies are sponsored by the pharmaceutical industry.

Report Description

The report on ‘Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Cognitive Impairment Associated with Schizophrenia (CIAS). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Cognitive Impairment Associated with Schizophrenia (CIAS).

The report on ‘Cognitive Impairment Associated with Schizophrenia (CIAS) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Cognitive Impairment Associated with Schizophrenia (CIAS)
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Cognitive Impairment Associated with Schizophrenia (CIAS)
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary